Business
Appointment of new Chief Financial Officer
Appointment of new Chief Financial Officer.
About this update from Ondine Biomedical, Inc.
[{"type":"text","content":"\n\n16 January 2024\n \nONDINE BIOMEDICAL INC.\n \n(\"Ondine Biomedical\", \"Ondine\" or the \"Company\")\n \nAppointment of new Chief Financial Officer\nCanadian life sciences company Ondine Biomedical Inc. (LON: OBI) has appointed Joseph P. (\"JP\") Errico as Chief Financial Officer.[i] JP will be responsible for managing and developing Ondine's finance function, as well as managing the capital markets interface, participating in discussions with large health systems and customers, and working closely with the management team on overall growth strategy, both from a financial and operational perspective.\nJP has successfully founded and sold (or taken public) several medical device and pharmaceutical companies, including ElectroCore, Fastenetix, K2 Medical Systems, AD4-Pharma, E2, and SpineCore, with his patented products generating over $20 billion in sales.\nCarolyn Cross, CEO and founder of Ondine commented:\n\"We are delighted that JP has agreed to join Ondine at this exciting time. His experience in finance, capital markets and developing medtech companies will be invaluable as we move forward with our international expansion and achieving FDA approval in conjunction with our partner HCA Healthcare.\"\nJP Errico commented:\n\"Ondine represents a unique opportunity to create shareholder value while heading off one of humanity's greatest health threats, antimicrobial resistance. I am proud to be joining an excellent team of professionals as Ondine brings this critically needed technology to the world.\"\nJP's educational background includes an undergraduate degree in Aeronautical Engineering from the Massachusetts Institute of Technology and graduate degrees in both Law and Mechanical/Materials Engineering from Duke University. He is also a trained patent attorney.\n*ENDS*\nEnquiries:\n \n\n\n\n\nOndine Biomedical Inc. \n\n\n \n\n\n\n\nAngelika Vance, Corporate Communications\n\n\n+001 (604) 838 2702\n\n\n\n\n \n\n\n \n\n\n\n\nSinger Capital Markets (Nominated Adviser and Joint Broker)\n\n\n \n\n\n\n\nAubrey Powell, Asha Chotai, Sam Butcher\n\n\n+44 (0)20 7496 3000\n\n\n\n\n \n\n\n \n\n\n\n\nRBC Capital Markets (Joint Broker)\n\n\n \n\n\n\n\nRupert Walford, Kathryn Deegan\n\n\n+44 (0)20 7653 4000\n\n\n\n\n\n\n\n \n\n\n\n\nVan...